Ovarian cancer
Not recruitingStudy on Eye Health During Treatment with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate for Patients with Recurrent Ovarian Cancer
Study on Eye Health During Treatment with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate for Patients with Recurrent Ovarian Cancer
- Disease:Ovarian cancer
- Substances:Brimonidine TartratePrednisolone Acetate+1
Ireland- Participants:18–64 years · 65+ years
- Substances:Brimonidine Tartrate
- Sponsor:AbbVie Deutschland GmbH & Co. KG











